Structure–activity study of novel tricyclic benzazepine arginine vasopressin antagonists
摘要:
Novel tricyclic benzazepine derivatives were synthesized as arginine vasopressin (AVP) antagonists. Several tricyclic compounds showed potent antagonistic activity in rat AVP receptors V-1a and V-2. Derivatives containing pyrrolo-tricyclic amines, 13i-k. 30, and 31 also showed selectivity for the V-2 receptor. (C) 2003 Elsevier Science Ltd. All rights reserved.
Tricyclic compounds of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds.
Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists
申请人:American Cyanamid Company
公开号:US05686445A1
公开(公告)日:1997-11-11
Tricyclic compounds of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds.
N-acylated tricyclic azaheterorings useful as vasopressin antagonists
申请人:American Cyanamid Company
公开号:EP0640592B1
公开(公告)日:1998-12-30
[EN] TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS<br/>[FR] COMPOSES TRICYCLIQUES DE BENZAZEPINE ANTAGONISTES DE LA VASOPRESSINE
申请人:AMERICAN CYANAMID COMPANY
公开号:WO1997047625A1
公开(公告)日:1997-12-18
(EN) Tricyclic compounds of general formula (I) as defined herein which exhibit antagonist activity at V1 and/or V2 receptors and exhibit $i(in vivo) vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds.(FR) Cette invention concerne des composés tricycliques représentés par la formule (I) qui présentent une activité antagoniste dirigée contre les récepteurs V1 et/ou V2 et présentent $i(in vivo) une activité antagoniste dirigée contre la vasopressine. L'invention se rapporte également à des procédés d'utilisation de ces composés pour traiter des maladies caractérisées par une absorption rénale excessive d'eau ainsi qu'à des procédés de préparation de ces composés.
Tricyclic benzazepine vasopressin antagonists
申请人:American Cyanamid Company
公开号:US05512563A1
公开(公告)日:1996-04-30
Tricyclic compounds of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds.